Current controversies in the management of early breast cancer

Clinical and Translational Oncology

Volumn 9, Issue 6, 2007, Pages 375-384

  Estevez L G ^a   Martin M ^b   Alba, E ^c   Colomer, R ^d   Lobo, F ^e   Lluch, A ^f   Adrover, E ^g   Albanell, J ^h   Barnadas, A ⁱ   Garcia Mata J ^j   Llombart, A ^k   Munoz M ^l   Rodriguez C ^m   Sanchez Rovira P ⁿ   Segui M A ^o   Tusquets, I ^h  

^a HM Hospitales Centro Integral Oncológico Hospital de Madrid Clara Campal   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^d MD ANDERSON CANCER CENTER   (Spain)

^e Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j Instituto de Investigación Biomédica Ourense Vigo Pontevedra   (Spain)

^k HOSPITAL ARNAU DE VILANOVA   (Spain)

^l INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^m HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁿ Allergy Section   (Spain)

^o HOSPITAL DE SABADELL   (Spain)

more..

Author keywords

Breast cancer; Controversial; Treatment

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GOSERELIN; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DRUG INDICATION; DRUG MECHANISM; EARLY DIAGNOSIS; ENDOCRINE FUNCTION; GENE OVEREXPRESSION; HEART DISEASE; HUMAN; MEDICAL DECISION MAKING; MEDICAL EXPERT; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; PATIENT EDUCATION; PREGNANCY; PREMENOPAUSE; QUALITY OF LIFE; REVIEW; SENTINEL LYMPH NODE BIOPSY; TREATMENT INDICATION; WOMEN'S HEALTH; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROTO ONCOGENE;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; NEOADJUVANT THERAPY; OVARIECTOMY; SENTINEL LYMPH NODE BIOPSY;

EID: 34848913472     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0070-z     Document Type: Review

References (85)

1. Lyckholm L (2001) Dealing with stress, burnout, and grief in the practice of oncology. Lancet Oncol 2:750-755
2. Grunfeld E, Whelan TJ, Zitzelsberger L et al (2000) Cancer care workers in Ontario: Prevalence of burnout, job stress and job satisfaction. CMAJ 163:166-169
3. Whippen DA, Canellos GP (1991) Burnout syndrome in the practice of oncology: Results of a random survey of 1,000 oncologists. J Clin Oncol 9:1916-1920
4. Veronesi U, Galiberti V, Zurrida S (1993) Prognostic significance of number and level of axillary node metastases in breast cancer. Breast 2:224-228
5. Schell SR (2006) Patient outcomes after axillary lymph node dissection for breast cancer: Use of postoperative continuous local anesthesia infusion. J Surg Res 134:124-132
6. Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 339:941-946
7. Wilke LG, McCall LM, Posther KE et al (2006) Surgical complications associated with sentinel lymph node biopsy: Results from a prospective international cooperative group trial. Ann Surg Oncol 13:491-500
8. Purushotham AD, Upponi S, Klevesath MB et al (2005) Morbidity after sentinel lymph node biopsy in primary breast cancer: Results from a randomized controlled trial. J Clin Oncol 23:4312-4321
9. Greene FL, Page DL, Fleming ID et al (2002) AJCC Cancer Staging Manual, 6th Edn. Springer-Verlag, New York, NY, p. 480
10. Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546-553
11. Julian TB, Krag D, Brown A (2004) A randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Breast Cancer Res Treat [Suppl 19]
12. Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703-7720
13. Krag D (2001) Minimal invasive staging for breast cancer: Clinical experience with sentinel lymph node biopsy. Semin Oncol 28:229-235
14. Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493
15. Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174
16. Breslin TM, Cohen L, Sahin A et al (2000) Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18:3480-3486
17. Julian TB, Patel N, Dusi D et al (2001) Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 182:407-410
18. Mamounas EP, Brown A, Anderson S et al (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23:2694-2702
19. Piato JR, Barros AC, Pincerato KM et al (2003) Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. A pilot study. Eur J Surg Oncol 29:118-120
20. Nason KS, Anderson BO, Byrd DR et al (2000) Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89:2187-2194
21. Stearns V, Ewing CA, Slack R et al (2002) Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9:235-242
22. Fernandez A, Cortes M, Benito E et al (2001) Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 22:361-366
23. Orr RK (1999) The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis. Ann Surg Oncol 6:109-116
24. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717
25. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
26. Press MF, Bernstein L, Thomas PA et al (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904
27. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274
28. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
29. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
30. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
31. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820
32. Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium, Abstract 1
33. Slamon D, Eiermann W, Robert N et al (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium, Abstract 52
34. Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819
35. Kell MR, Power CP (2005) Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment. BMJ 331:1202
36. Neyt M, Albrecht J, Cocquyt V (2006) An economic evaluation of Herceptin(R) in adjuvant setting: The Breast Cancer International Research Group 006 trial. Ann Oncol 17:381-390
37. Dent R, Clemons M (2005) Adjuvant trastuzumab for breast cancer. BMJ 331:1035-1036
38. Thornton H (2005) Adjuvant trastuzumab for breast cancer: Advent of pharmacogenetics raises many issues. BMJ 331:1202
39. Braun M, Hasson-Ohayon I, Perry S et al (2005) Motivation for giving birth after breast cancer. Psychooncology 14:282-296
40. Cnattingius S, Torrang A, Ekbom A et al (2005) Pregnancy characteristics and maternal risk of breast cancer. JAMA 294:2474-2480
41. Kroman N, Mouridsen HT (2003) Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. Breast 12:516-521
42. Russo J, Moral R, Balogh GA et al (2005) The protective role of pregnancy in breast cancer. Breast Cancer Res 7:131-142
43. Whiteman MK, Hillis SD, Curtis KM et al (2004) Reproductive history and mortality after breast cancer diagnosis. Obstet Gynecol 104:146-154
44. Cullinane CA, Lubinski J, Neuhausen SL et al (2005) Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 117:988-991
45. Blakely LJ, Buzdar AU, Lozada JA et al (2004) Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 100:465-469
46. Gelber S, Coates AS, Goldhirsch A et al (2001) Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 19:1671-1675
47. Kroman N, Jensen MB, Melbye M et al (1997) Should women be advised against pregnancy after breast-cancer treatment? Lancet 350:319-322
48. Malamos NA, Stathopoulos GP, Keramopoulos A et al (1996) Pregnancy and offspring after the appearance of breast cancer. Oncology 53:471-475
49. Sankila R, Heinavaara S, Hakulinen T (1994) Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect". Am J Obstet Gynecol 170:818-823
50. Sutton R, Buzdar AU, Hortobagyi GN (1990) Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 65:847-850
51. Ariel IM, Kempner R (1989) The prognosis of patients who become pregnant after mastectomy for breast cancer. Int Surg 74:185-187
52. Velentgas P, Daling JR, Malone KE et al (1999) Pregnancy after breast carcinoma: Outcomes and influence on mortality. Cancer 85:2424-2432
53. Mueller BA, Simon MS, Deapen D et al (2003) Childbearing and survival after breast carcinoma in young women. Cancer 98:1131-1140
54. von Schoultz E, Johansson H, Wilking N, Rutqvist LE (1995) Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 13:430-434
55. Upponi SS, Ahmad F, Whitaker IS, Purushotham AD (2003) Pregnancy after breast cancer. Eur J Cancer 39:736-741
56. Tewari K, Bonebrake RG, Asrat T, Shanberg AM (1997) Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 350:183
57. Cullins SL, Pridjian G, Sutherland CM (1994) Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. JAMA 271:1905-1906
58. Barthelmes L, Gateley CA (2004) Tamoxifen and pregnancy. Breast 13:446-451
59. Jakesz R, Hausmaninger H, Kubista E et al (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627
60. Taylor CW, Green S, Dalton WS et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. J Clin Oncol 16:994-999
61. Clarke MJ (1998) Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. BMJ 317:1246-1248
62. Kaufmann M, Jonat W, Blamey R et al (2003) Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39:1711-1717
63. - (1993) Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet 341:1293-1298
64. Ejlertsen B, Dombernowski P, Mouridsen HT (1999) Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proc Am Soc Clin Oncol 248
65. Von Minckwitz G, Graf E, Geberth M (2004) Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 Trial. Proc Am Soc Clin Oncol 534
66. Castiglione-Gertsch M, O'Neill A, Price KN et al (2003) Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 95:1833-1846
67. Schmid HH (1961) [Breast cancer and pregnancy]. Z Geburtshilfe Gynakol 157:275-295
68. Wallwiener D, Possinger K, Schmid P (2004) A phase III trial comparing adjuvant treatment with leuprorelin acetate 3M-Depot for 24 months with CMF chemotherapy in ER/PR+ node+pre-perimenopausal breast cancer patients. Proc Am Soc Clin Oncol 533
69. Robert NJ, Wang M, Cella D (2003) Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer <3 cm. Proc Am Soc Clin Oncol 16
70. Lars R (1999) Zoladex™ and Tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Research Campaign (C.R.C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, The South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.I.V.I.O). Proc Am Soc Clin Oncol 251
71. Boccardo F, Rubagotti A, Amoroso D et al (2000) Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718-2727
72. Roche H, Kerbrat P, Bonneterre J (2000) Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients with positive hormone-receptor and 1-3 node-positive tumour: Results of the FASG 06 trial. Proc Am Soc Clin Oncol 279
73. Arriagada R, Le MG, Spielmann M et al (2005) Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 16:389-396
74. Davidson NE, O'Neill AM, Vukov AM et al (2005) Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol 23:5973-5982
75. Baum M, O'shaughnessy JA (2002) Management of premenopausal women with early-stage breast cancer: Is there a role for ovarian suppression? Clin Breast Cancer 3:260-267
76. Parulekar WR, Day AG, Ottaway JA et al (2005) Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study - NCIC CTG MA.5. J Clin Oncol 23:6002-6008
77. Wirk B (2005) The role of ovarian ablation in the management of breast cancer. Breast J 11:416-424
78. Del Mastro L, Venturini M, Sertoli MR, Rosso R (1997) Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: Prognostic role and clinical implications. Breast Cancer Res Treat 43:183-190
79. Groenvold M, Fayers PM, Petersen MA, Mouridsen HT (2006) Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: Impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat 98:275-284
80. International Breast Cancer Study Group (2002) Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 94:1054-1065
81. Arriagada R, Spielmann M, Koscielny S et al (2005) Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol 44:458-466
82. Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991
83. Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583
84. Duric VM, Stockler MR, Heritier S et al (2005) Patients' preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now? Ann Oncol 16:1786-1794
85. Chao C, Studts JL, Abell T et al (2003) Adjuvant chemotherapy for breast cancer: How presentation of recurrence risk influences decision-making. J Clin Oncol 21:4299-4305